Crescendo Biologics, the drug developer of novel, targeted T-cell enhancing therapeutics, has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer.
Dr Williams will manage Crescendo’s internal CMC activities and the strategic CDMO partner, ensuring the smooth transition of its products through development into the clinic. Dr Williams has more than 20 years’ experience in the biopharmaceutical industry, in particular in CMC project management and development of monoclonal antibody-based products.
Prior to joining Crescendo, Dr Williams was VP CMC at Kymab, where he established their internal CMC development functions and managed a network of contract manufacturing organisations. Dr Williams has also held senior positions at Crucell (Janssen vaccines), CAT/Medimmune, Acambis and Schering Plough Animal Health.
Dr Williams received his PhD from the University of Surrey, Guildford, UK.
Phil Bland-Ward, Chief Scientific Officer of Crescendo Biologics, said: "Richard comes with exceptional experience in CMC and development. His appointment is a significant step forwards for Crescendo and speaks to the attractiveness of our pipeline of multi-specific T-cell enhancers – all with novel modes of action."
“We look forward to working with Richard as we quickly progress towards the clinic.”
Dr Williams commented: "I am excited to join Crescendo and to help accelerate CB307, a CD137-PSMA T-cell enhancer, and the pipeline of next generation immuno-oncology therapeutics, towards the clinic. Working alongside our newly appointed and internationally recognised CDMO, we will be able to demonstrate the enormous therapeutic potential that our versatile Humabody products hold.”
